ClinicalTrials.gg
CompletedNCT04057573Updated Aug 22, 2025Results posted

Topical Ruxolitinib Evaluation in Vitiligo Study 2 (TRuE-V2)

A Phase 3 interventional study of Ruxolitinib cream and Vehicle in Non-segmental Vitiligo, sponsored by Incyte Corporation. Completed at 76 sites in 9 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2025-08-22.

Sponsored by Incyte Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
344
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing ruxolitinib in Vitiligo — 5 open to participants now, 5 under way, 4 of them phase 3. ruxolitinib · Vitiligo.

Enrollment
2nd of 14
344 · median 90
Started
2019
with 1 other
Phase 3
6 of 14
3 open now
Registered
4th of 14
by date
Lead sponsor
9 of 14
Incyte Corporation

Among the 14 studies testing ruxolitinib in Vitiligo, this one is the 2nd largest by enrollment, is one of 2 that started in 2019, is one of 6 in phase 3, and was the 4th registered.

Vitiligo

343 studies on the registry are indexed under Vitiligo; 96 are open to participants now.

Browse Vitiligo studies →

Open to participants now

5 of the 14 studies testing ruxolitinib in Vitiligo are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About ruxolitinib

ruxolitinib: first FDA approval 2011 (JAKAFI), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 48 Vitiligo studies recruiting now, 13 (27%) set no upper age limit and 29 (60%) stop at 75 or younger; 18 take children under 18; 8 take healthy volunteers.

This study: 12 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing ruxolitinib in Vitiligo, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adolescent and adult participants with non-segmental vitiligo for whom total body involved vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).

03

Conditions studied

  • Non-segmental Vitiligo

Browse trials for

Keywords

  • Vitiligo
  • non-segmental
  • JAK inhibitor
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Clinical diagnosis of non-segmental vitiligo with depigmented area including ≥ 0.5% BSA on the face, ≥ 0.5 F-VASI, ≥ 3% BSA on nonfacial areas, ≥ 3 T-VASI, and total body vitiligo area (facial and nonfacial) not exceeding 10% BSA.
  • Agree to discontinue all agents used to treat vitiligo from screening through the final safety follow-up visit. Over-the-counter preparations deemed acceptable by the investigator and camouflage makeups are permitted.
  • Must be willing to take appropriate measures to avoid pregnancy or fathering a child for the duration of study participation.

Key Exclusion Criteria:

  • No pigmented hair within any of the vitiligo areas on the face.
  • Other forms of vitiligo (eg, segmental) or other differential diagnosis of vitiligo or other skin depigmentation disorders (eg, piebaldism, pityriasis alba, leprosy, postinflammatory hypopigmentation, progressive macule hypomelanosis, nevus anemicus, chemical leukoderma, and tinea versicolor).
  • Have used depigmentation treatments (eg, monobenzone) for past treatment of vitiligo or other pigmented areas.
  • Use of protocol-defined treatments within the indicated before baseline.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
344 participants (actual)

Study arms

  • Experimental
    Double-Blind Period: Ruxolitinib cream 1.5% BID

    Participants applied ruxolitinib 1.5% cream twice daily (BID) for 24 weeks.

    Drug: Ruxolitinib cream

  • Placebo comparator
    Double-Blind Period: Vehicle cream BID

    Participants applied matching vehicle cream BID for 24 weeks.

    Drug: Vehicle

  • Experimental
    Treatment-Extension Period: Ruxolitinib cream 1.5% BID

    Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied ruxolitinib cream 1.5% BID during the Double-Blind Period continued to apply ruxolitinib cream 1.5% BID for an additional 28 weeks in the Treatment-Extension Period.

    Drug: Ruxolitinib cream

  • Experimental
    Treatment-Extension Period: Vehicle cream to Ruxolitinib cream 1.5% BID

    Participants who completed the Week 24 assessments with no safety concerns could continue into the 28-week Treatment-Extension Period. Participants who applied vehicle cream BID during the Double-Blind Period applied ruxolitinib cream 1.5%m BID for 28 weeks in the Treatment-Extension Period.

    Drug: Ruxolitinib cream · Drug: Vehicle

Interventions

  • Ruxolitinib cream is a topical formulation applied as a thin film to affected areas.

    Also known as: INCB018424 cream

  • DrugVehicle

    Vehicle cream is a topical formulation applied as a thin film to affected areas.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24

    An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

Secondary outcomes

  1. Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 24

    An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

  2. Percentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 24

    An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

  3. Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 24

    A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

  4. Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 24

    The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.

    Time frame: Baseline; Week 24

  5. Percentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24

    F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 24

  6. Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period

    An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

    Time frame: from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to Week 24)

  7. Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

    Time frame: from the completion of the Week 24 assessments until at least 30 days after the last application of study drug (up to Week 52 + 30 days)

  8. Percentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 24

    An F-VASI25 responder achieved at least 25% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

  9. Percentage of Participants Achieving a ≥ %25, ≥ %50, ≥ 75%, and ≥ 90% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25/50/75/90) Score at Week 52

    An F-VASI25/50/75/90 responder achieved at least 25/50/75/90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

    Time frame: Baseline; Week 52

  10. Percentage Change From Baseline in F-VASI at Week 24

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 24

  11. Percentage Change From Baseline in F-VASI at Week 52

    F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 52

  12. Percentage Change From Baseline in F-BSA at Week 52

    F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 52

  13. Percentage Change From Baseline in T-VASI at Week 24

    T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 24

  14. Percentage Change From Baseline in T-VASI at Week 52

    T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 52

  15. Percentage Change From Baseline in T-BSA at Week 24

    T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 24

  16. Percentage Change From Baseline in T-BSA at Week 52

    T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

    Time frame: Baseline; Week 52

  17. Percentage of Participants Achieving a ≥ 25%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/75/90) Score at Week 24

    A T-VASI25/75/90 responder achieved at least 25/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; Week 24

  18. Percentage of Participants Achieving a ≥ 25%, ≥ 50%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/50/75/90) Score at Week 52

    A T-VASI25/50/75/90 responder achieved ≥25/50/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

    Time frame: Baseline; Week 52

  19. Percentage of Participants in Each Category of VNS During the Treatment Period (Double-Blind and Treatment-Extension Periods)

    The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.

    Time frame: Baseline; Week 24 and Week 52

  20. Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24

    The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "Prevented work or studying" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

    Time frame: Baseline; Week 24

  21. Change From Baseline in DLQI at Week 52

    The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "Prevented work or studying" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

    Time frame: Baseline; Week 52

  22. Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) During the Treatment Period (Double-Blind and Treatment-Extension Periods)

    The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. The CDLQI is the youth/children's version of the DLQI and was completed by adolescents aged ≥ 12 years to \< 16 years. Each question is scored as: very much = 3; quite a lot = 2; only a little = 1; not at all = 0; question unanswered = 0. For Question 7: "Prevented school" = 3. The CDLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

    Time frame: Baseline; Week 24 and Week 52

  23. Trough Plasma Concentrations of Ruxolitinib at Weeks 4, 24, and 40

    Trough plasma concentration was defined as the measurement of the plasma concentration of ruxolitinib before drug application.

    Time frame: pre-dose at Weeks 4, 24, and 40

07

Results

Posted Sep 21, 2022
Limitations and caveats
Data from participants at a single site were excluded from all efficacy analyses done on the Intent-to-Treat Population owing to serious noncompliance with the protocol resulting in serious concerns with the data quality.

Participant flow

This study was conducted at 49 study centers in North America and Europe.

24-Week Double-Blind Period
Participant flow — 24-Week Double-Blind Period
MilestoneDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Started22911500
Itt population22911500
Itt population, excluding non-compliant site22210900
Completed1999800
Not completed301700
Withdrew: Adverse event2000
Withdrew: Lack of efficacy0100
Withdrew: Lost to follow-up11600
Withdrew: Physician decision1000
Withdrew: Pregnancy1000
Withdrew: Withdrawal by subject10800
Withdrew: Discontinued treatment due to covid-19 pandemic3100
Withdrew: Non-compliance with attending study visits1000
Withdrew: Unable to attend study visits due to travel0100
Withdrew: Not treated1000
28-Week Treatment Extension Period
Participant flow — 28-Week Treatment Extension Period
MilestoneDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Started0019998
Completed0017879
Not completed002119
Withdrew: Adverse event0010
Withdrew: Lack of efficacy0010
Withdrew: Lost to follow-up00910
Withdrew: Withdrawal by subject0099
Withdrew: Unable to perform safety follow-up visit0010

Outcome measures

PrimaryPercentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24

An F-VASI75 responder achieved at least 75% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of body surface area \[BSA\]) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage of Participants Achieving a ≥ 75% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI75) Score at Week 2430.911.4
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = 0.0004 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 3.45 · 95% CI 1.737 to 6.835
SecondaryPercentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 24

An F-VASI50 responder achieved at least 50% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI50) Score at Week 2451.420.9
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = < 0.0001 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 3.99 · 95% CI 2.296 to 6.949
SecondaryPercentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 24

An F-VASI90 responder achieved at least 90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage of Participants Achieving a ≥ 90% Improvement From Baseline in the Face Vitiligo Area Scoring Index (F-VASI90) Score at Week 2416.31.3
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = 0.0065 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 15.29 · 95% CI 2.150 to 108.739
SecondaryPercentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 24

A T-VASI50 responder achieved at least 50% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage of Participants Achieving a ≥ 50% Improvement From Baseline in the Total Body Vitiligo Area Scoring Index (T-VASI50) Score at Week 2423.96.8
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = 0.0006 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 4.29 · 95% CI 1.865 to 9.853
SecondaryPercentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 24

The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage of Participants Achieving a Vitiligo Noticeability Scale (VNS) of 4 or 5 at Week 2420.54.9
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = 0.0013 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 4.86 · 95% CI 1.851 to 12.755
SecondaryPercentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24

F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-Baseline (BL) value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24
percentage changeDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage Change From Baseline in Facial Body Surface Area (F-BSA) at Week 24-26.4 ± 2.57-7.0 ± 3.82
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · ANCOVA · p = < 0.0001 (Response Variable = Treatment + Stratification Factors (Skin Type Fitzpatrick scale Type I, II versus Type III, IV, V, and VI, Region North America/Europe) + Baseline) · Least squares mean difference: -19.5 · 95% CI -28.46 to -10.45
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period

An adverse event (AE) was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

Time frame:
from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to Week 24)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period
ParticipantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Double-Blind Period11439
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could have been any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. A TEAE was defined as any AE reported for the first time or the worsening of a pre-existing event after the first application of study drug.

Time frame:
from the completion of the Week 24 assessments until at least 30 days after the last application of study drug (up to Week 52 + 30 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period
ParticipantsTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Number of Participants With Treatment-emergent Adverse Events (TEAEs) During the Treatment-Extension Period8238
SecondaryPercentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 24

An F-VASI25 responder achieved at least 25% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage of Participants Achieving a ≥ 25% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25) Score at Week 2463.932.0
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = < 0.0001 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 3.76 · 95% CI 2.267 to 6.246
SecondaryPercentage of Participants Achieving a ≥ %25, ≥ %50, ≥ 75%, and ≥ 90% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25/50/75/90) Score at Week 52

An F-VASI25/50/75/90 responder achieved at least 25/50/75/90% improvement from Baseline in F-VASI, measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement).

Time frame:
Baseline; Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ %25, ≥ %50, ≥ 75%, and ≥ 90% Improvement in the Face Vitiligo Area Scoring Index (F-VASI25/50/75/90) Score at Week 52
percentage of participantsTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
F-VASI2582.571.6
F-VASI5074.049.4
F-VASI7548.029.6
F-VASI9027.716.0
SecondaryPercentage Change From Baseline in F-VASI at Week 24

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline in F-VASI at Week 24
percentage changeDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage Change From Baseline in F-VASI at Week 24-44.39 ± 2.85-15.80 ± 4.04
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · mixed-effect model; repeated measurement · p = <0.0001 · Least squares mean difference: -28.59 · 95% CI -38.33 to -18.86
SecondaryPercentage Change From Baseline in F-VASI at Week 52

F-VASI was measured by the percentage of vitiligo involvement (percentage of BSA) and the degree of depigmentation: 0% (no depigmentation), 10% (only specks of depigmentation), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment), or 100% (no pigment). The percentage of BSA (hand unit) vitiligo involvement was estimated to the nearest 0.1% by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate the percentage of BSA vitiligo involvement. F-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site on the face and summing the values of all sites (possible range: 0-3; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 52
Reported as:
Mean · percentage change
Percentage Change From Baseline in F-VASI at Week 52
percentage changeTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Percentage Change From Baseline in F-VASI at Week 52-63.75 ± 34.103-43.50 ± 47.509
SecondaryPercentage Change From Baseline in F-BSA at Week 52

F-BSA involvement was the proportion of the facial body surface area with vitiligo. The area "Face" was defined as including the area on the forehead to the original hairline, on the cheek to the jawline vertically to the jawline and laterally from the corner of the mouth to the tragus. The area "Face" did not include surface area of the lips, scalp, ears, or neck, but included the nose and eyelids. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 52
Reported as:
Mean · percentage change
Percentage Change From Baseline in F-BSA at Week 52
percentage changeTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Percentage Change From Baseline in F-BSA at Week 52-41.81 ± 35.694-23.45 ± 46.360
SecondaryPercentage Change From Baseline in T-VASI at Week 24

T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline in T-VASI at Week 24
percentage changeDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage Change From Baseline in T-VASI at Week 24-28.85 ± 1.96-8.99 ± 2.78
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · mixed-effect model; repeated measurement · p = <0.0001 · Least squares mean difference: -19.85 · 95% CI -26.55 to -13.16
SecondaryPercentage Change From Baseline in T-VASI at Week 52

T-VASI was calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to the nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement). Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 52
Reported as:
Mean · percentage change
Percentage Change From Baseline in T-VASI at Week 52
percentage changeTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Percentage Change From Baseline in T-VASI at Week 52-46.80 ± 29.903-30.11 ± 30.315
SecondaryPercentage Change From Baseline in T-BSA at Week 24

T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · percentage change
Percentage Change From Baseline in T-BSA at Week 24
percentage changeDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Percentage Change From Baseline in T-BSA at Week 24-14.23 ± 1.55-2.28 ± 2.19
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · mixed-effect model; repeated measurement · p = <0.0001 · Least squares mean difference: -11.95 · 95% CI -17.23 to -6.67
SecondaryPercentage Change From Baseline in T-BSA at Week 52

T-BSA involvement was the proportion of the body surface area with vitiligo. Body surface area assessment was performed by the Palmar Method. Body surface area was estimated to the nearest 0.1%. The approximate size of the participant's entire palmar surface (i.e., the palm plus 5 digits) was considered as 1% BSA, and the approximate size of the participant's thumb was considered as 0.1% BSA. Percentage change = (\[post-BL value minus BL value\]/BL value) X 100.

Time frame:
Baseline; Week 52
Reported as:
Mean · percentage change
Percentage Change From Baseline in T-BSA at Week 52
percentage changeTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Percentage Change From Baseline in T-BSA at Week 52-26.04 ± 28.481-13.54 ± 27.144
SecondaryPercentage of Participants Achieving a ≥ 25%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/75/90) Score at Week 24

A T-VASI25/75/90 responder achieved at least 25/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; Week 24
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 25%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/75/90) Score at Week 24
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
T-VASI2550.221.2
T-VASI758.01.8
T-VASI901.00.0
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = < 0.0001 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 3.75 · 95% CI 2.121 to 6.630
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · exact logistic regression · p = 0.0436 (The model included the treatment group (1.5% BID and vehicle) and stratification factors (skin type and region).) · Odds ratio (or): 4.59 · 95% CI 1.045 to 20.192
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · Odds ratio (or): 1.35
SecondaryPercentage of Participants Achieving a ≥ 25%, ≥ 50%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/50/75/90) Score at Week 52

A T-VASI25/50/75/90 responder achieved ≥25/50/75/90% improvement from Baseline in T-VASI, calculated with contributions from 6 sites. The percentage of vitiligo involvement was estimated in hand units (percentage of BSA estimated to nearest 0.1%) by the Investigator using the Palmar Method. The Investigator used his/her hand to mimic the participant's hand size to evaluate percent BSA vitiligo involvement. The degree of depigmentation for each site was estimated to the nearest percentage: 0% (no depigmentation present), 10% (only specks of depigmentation present), 25% (pigmented area exceeded depigmented area), 50% (depigmented and pigmented area was equal), 75% (depigmented area exceeded pigmented area), 90% (specks of pigment present), 100% (no pigment present). T-VASI was then derived by multiplying the values assessed for the vitiligo involvement by the percentage of affected skin for each site and summing the values (range: 0-100; lower scores indicate increased improvement).

Time frame:
Baseline; Week 52
Reported as:
Number · percentage of participants
Percentage of Participants Achieving a ≥ 25%, ≥ 50%, ≥ 75%, and ≥ 90% Improvement in the Total Body Vitiligo Area Scoring Index (T-VASI25/50/75/90) Score at Week 52
percentage of participantsTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
T-VASI2576.853.1
T-VASI5049.222.2
T-VASI7520.98.6
T-VASI906.81.2
SecondaryPercentage of Participants in Each Category of VNS During the Treatment Period (Double-Blind and Treatment-Extension Periods)

The VNS is a patient-reported measure of vitiligo treatment success that is rated on a 5-point scale. The Baseline facial photograph was shown to the participants for reference, and a mirror was provided for the participants to assess the vitiligo on their face. The participant was asked to respond to the following query: Compared with before treatment, how noticeable is the vitiligo now? Responses: (1) more noticeable, (2) as noticeable, (3) slightly less noticeable, (4) a lot less noticeable, and (5) no longer noticeable.

Time frame:
Baseline; Week 24 and Week 52
Reported as:
Number · percentage of participants
Percentage of Participants in Each Category of VNS During the Treatment Period (Double-Blind and Treatment-Extension Periods)
percentage of participantsDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Week 24, more noticeable8.511.2——
Week 24, as noticeable30.758.2——
Week 24, slightly less noticeable40.225.5——
Week 24, a lot less noticeable20.64.1——
Week 24, no longer noticeable0.01.0——
Week 52, more noticeable——4.511.1
Week 52, as noticeable——16.425.9
Week 52, slightly less noticeable——46.349.4
Week 52, a lot less noticeable——32.213.6
Week 52, no longer noticeable——0.60.0
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) at Week 24

The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "Prevented work or studying" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

Time frame:
Baseline; Week 24
Reported as:
Least squares mean · scores on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24
scores on a scaleDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BID
Change From Baseline in Dermatology Life Quality Index (DLQI) at Week 24-1.19 ± 0.30-0.59 ± 0.41
Statistical analysis
  • Double-Blind Period: Ruxolitinib Cream 1.5% BID vs Double-Blind Period: Vehicle Cream BID · mixed-effect model; repeated measurement · p = 0.2350 · Least squares mean difference: -0.60 · 95% CI -1.60 to 0.39
SecondaryChange From Baseline in DLQI at Week 52

The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. Each question is scored as: very much = 3; a lot = 2; a little = 1; not at all = 0; not relevant = 0. For Question 7, "Prevented work or studying" = 3. The DLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

Time frame:
Baseline; Week 52
Reported as:
Mean · scores on a scale
Change From Baseline in DLQI at Week 52
scores on a scaleTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Baseline4.37 ± 4.4855.38 ± 4.876
Week 52-0.84 ± 3.976-1.15 ± 4.264
SecondaryChange From Baseline in Children's Dermatology Life Quality Index (CDLQI) During the Treatment Period (Double-Blind and Treatment-Extension Periods)

The DLQI is a 10-question validated questionnaire for use in participants aged 16 years and over to measure how much the skin problem has affected the participant over the previous 7 days. The CDLQI is the youth/children's version of the DLQI and was completed by adolescents aged ≥ 12 years to \< 16 years. Each question is scored as: very much = 3; quite a lot = 2; only a little = 1; not at all = 0; question unanswered = 0. For Question 7: "Prevented school" = 3. The CDLQI was calculated by summing the score of each question, resulting in a maximum of 30 and a minimum of 0. The higher the score, the more quality of life is impaired.

Time frame:
Baseline; Week 24 and Week 52
Reported as:
Mean · scores on a scale
Change From Baseline in Children's Dermatology Life Quality Index (CDLQI) During the Treatment Period (Double-Blind and Treatment-Extension Periods)
scores on a scaleDouble-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Baseline1.29 ± 2.2016.33 ± 10.116——
Week 240.00 ± 1.837-2.33 ± 8.505——
Week 52——1.19 ± 4.665-1.00 ± 4.583
SecondaryTrough Plasma Concentrations of Ruxolitinib at Weeks 4, 24, and 40

Trough plasma concentration was defined as the measurement of the plasma concentration of ruxolitinib before drug application.

Time frame:
pre-dose at Weeks 4, 24, and 40
Reported as:
Mean · nanomoles
Trough Plasma Concentrations of Ruxolitinib at Weeks 4, 24, and 40
nanomolesRuxolitinib CreamDouble-Blind Period: Vehicle Cream BIDTreatment-Extension Period: Ruxolitinib Cream 1.5% BIDTreatment-Extension Period: Vehicle Cream to Ruxolitinib Cream 1.5% BID
Week 461.0 ± 68.6———
Week 2454.5 ± 79.1———
Week 40——57.0 ± 73.348.2 ± 57.0

Adverse events

Collected over from the time of Informed Consent Form signing until at least 30 days after the last application of study drug (up to Week 52 + 30 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vehicle Cream BID0/115 (0%)0/115 (0%)6/115 (5.2%)
Ruxolitinib Cream 1.5% BID0/326 (0%)6/326 (1.8%)56/326 (17.2%)
Most frequent serious events
Most frequent serious events
EventVehicle Cream BIDRuxolitinib Cream 1.5% BID
Appendiceal abscessInfections and infestations0/1151/326
Coronary artery stenosisCardiac disorders0/1151/326
Joint dislocationInjury, poisoning and procedural complications0/1151/326
Papillary thyroid cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/1151/326
RhabdomyolysisMusculoskeletal and connective tissue disorders0/1151/326
UreterolithiasisRenal and urinary disorders0/1151/326
Most frequent other events
Most frequent other events
EventVehicle Cream BIDRuxolitinib Cream 1.5% BID
COVID-19Infections and infestations2/11524/326
Application site acneGeneral disorders3/11520/326
NasopharyngitisInfections and infestations1/11517/326

Baseline characteristics

Baseline data are reported for members of the Safety Population, comprised of all participants who applied ruxolitinib cream or vehicle cream at least once. Treatment groups for this population were determined according to the actual treatment the participant applied on Day 1.

Age, Continuous
Age, Continuous(years)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Mean38.4 ± 15.2239.8 ± 12.1238.9 ± 14.25
Sex: Female, Male
Sex: Female, Male(Participants)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Female11260172
Male11655171
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
White18293275
Black/African American12517
Asian12719
American Indian/Alaska Native101
Native Hawaiian/Pacific Islander202
Not Reported336
North African202
White/Caucasian and Asian101
Guyana101
Cape Verdean112
Persian101
Middle Eastern303
Arab/North-African101
White/Black/Asian101
Mexican213
Jordanian101
Arabic101
Argentinian101
Brazilian022
Dominican Republic011
Indo-Caribbean011
Multi-National011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Hispanic or Latino503282
Not Hispanic or Latino17480254
Not Reported235
Captured as "Other"202
Face Vitiligo Area Scoring Index (F-VASI)
Face Vitiligo Area Scoring Index (F-VASI)(scores on a scale)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Mean0.900 ± 0.52480.834 ± 0.52330.878 ± 0.5245
Facial Body Surface Area (F-BSA) Involvement
Facial Body Surface Area (F-BSA) Involvement(percentage of facial surface area)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Mean0.98 ± 0.5700.92 ± 0.5690.96 ± 0.569
Total Body Vitiligo Area Scoring Index (T-VASI)
Total Body Vitiligo Area Scoring Index (T-VASI)(scores on a scale)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Mean6.844 ± 2.05747.022 ± 2.19866.904 ± 2.1043
Total Body Surface Area (T-BSA) Involvement
Total Body Surface Area (T-BSA) Involvement(percentage of total body surface area)Double-Blind Period: Ruxolitinib Cream 1.5% BIDDouble-Blind Period: Vehicle Cream BIDTotal
Mean7.44 ± 2.0117.68 ± 2.0407.52 ± 2.021

8 further baseline measures are reported on the registry.

08

Study locations

76 sites
  • Desert Sky Dermatology
    Gilbert, Arizona 85295, United States
  • Center For Dermatology Cosmetic and Laser Surgery
    Fremont, California 94538, United States
  • Uci Beckman Laser Institute and Medical Clinic
    Irvine, California 92617, United States
  • UCI Health Beckman Laser Institute and Medical Center
    Irvine, California 92697, United States
  • Vitiligo & Pigmentation Institute of Southern California
    Los Angeles, California 90036, United States
  • Dermatology Research Associates
    Los Angeles, California 90045, United States
  • Dermatology Specialists Inc
    Murrieta, California 92562, United States
  • Dermatology Specialists Inc
    Oceanside, California 92056, United States
  • Integrative Skin Science and Research
    Sacramento, California 95815, United States
  • Acrc Studies
    San Diego, California 92119, United States
  • Central Sooner Research
    San Diego, California 92123, United States
  • Colorado Medical Research Center Inc
    Denver, Colorado 80210, United States
  • Advanced Pharma Cr
    Miami, Florida 33147, United States
  • Leavitt Medical Associates of Florida
    Ormond Beach, Florida 32174, United States
  • Avita Clinical Research
    Tampa, Florida 33613, United States
  • Olympian Clinical Research
    Tampa, Florida 33614, United States
  • Ashira Dermatology Llc
    Gurnee, Illinois 60031, United States
  • Randall Dermatology of West Lafayette
    West Lafayette, Indiana 47096, United States
  • Randall Dermatology
    West Lafayette, Indiana 47906, United States
  • Delricht Clinical Research - Clinedge - Ppds Baton Rouge
    Baton Rouge, Louisiana 70809, United States
  • Tufts Medical Center
    Boston, Massachusetts 02111, United States
  • Tufts Medical Center
    Boston, Massachusetts 02116, United States
  • Metro Boston Clinical Partners
    Brighton, Massachusetts 02135, United States
  • University of Massachusetts
    Worcester, Massachusetts 01655, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Henry Ford Medical Center
    Detroit, Michigan 48202, United States
  • Minnesota Clinical Study Center
    Minneapolis, Minnesota 55432, United States
  • Jdr Dermatology Research
    Las Vegas, Nevada 89148, United States
  • Northwell Physician Partners
    New Hyde Park, New York 11042, United States
  • Icahn School of Medicine At Mount Sinai
    New York, New York 10029, United States
  • Derm Research Center of New York Inc
    Stony Brook, New York 11790, United States
  • Central Sooner Research
    Norman, Oklahoma 73071, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • Clinical Research Partners Llc
    Richmond, Virginia 23220, United States
  • Medical Center Unimed Eood
    Sevlievo, 05400, Bulgaria
  • Medical Center Unimed EOOD
    Sevlievo, 5300, Bulgaria
  • Diagnostic Consultative Center Ii Sofia Eood
    Sofia, 01000, Bulgaria
  • University Multiprofile Hospital For Active Treatment Aleksandrovska
    Sofia, 01431, Bulgaria
  • Diagnostic Consultative Center II Sofia EOOD
    Sofia, 1000, Bulgaria
  • Diagnostic Consultative Center II Sofia EOOD
    Sofia, 1407, Bulgaria
  • University Hospital Prof Dr Stoyan Kirkovich
    Stara Zagora, 06003, Bulgaria
  • University Hospital " Prof. Dr Stoyan Kirkovich"
    Stara Zagora, 6003, Bulgaria
  • Simcoderm Medical and Surgical Dermatology Center
    Barrie, Ontario L4M 7G1, Canada
  • Kingsway Clinical Research
    Etobicoke, Ontario M8X 1Y9, Canada
  • Lynderm Research Inc
    Markham, Ontario L3P 1X2, Canada
  • K. Papp Clinical Research
    Waterloo, Ontario N2J 1C4, Canada
  • Xlr8 Medical Research
    Windsor, Ontario N8W 1E6, Canada
  • Centre Hospitalier Universitaire de Besancon
    Besançon, 25000, France
  • CHU Besancon
    Besançon, 25030, France
  • Centre Hospitalier Universitaire de Bordeaux
    Bordeaux, 33000, France
  • CHU de Bordeaux, Hospital Saint Andre
    Bordeaux, 33075, France
  • University Hospital Henri Mondor
    Créteil, 94000, France
  • CENTRE HOSpITALIER UNIVERSITAIRE HENRI MONDOR
    Créteil, 94010, France
  • Le Bateau Blanc
    Martigues, 13500, France
  • Emovis GMBH
    Berlin, 10629, Germany
  • Universitatsklinikum Bonn Aoer
    Bonn, 53127, Germany
  • Hautarztpraxis Mahlow
    Mahlow, 15831, Germany
  • Universitatsmedizin Der Johannes Gutenberg-Universitat Mainz Iii
    Mainz, 55131, Germany
  • University Medical Center (Universitätsmedizin der Johannes Gutenberg-Universität Mainz)
    Mainz, 55131, Germany
  • Policlinico S. Orsola Malpighi
    Bologna, 40138, Italy
  • Istituto Dermatologico San Gallicano
    Rome, 00163, Italy
  • Amsterdam University Medical Centre
    Amsterdam, 1105 AZ, Netherlands
  • Synexus Polska Sp. Z o.o. Oddział w Częstochowie
    Częstochowa, 42-202, Poland
  • Synexus Affiliate - Krakowskie Centrum Medyczne
    Krakow, 31-501, Poland
  • Synexus Polska Sp Z Oo Oddzial W Lodzi
    Lodz, 90-127, Poland
  • Synexus Polska Sp Z Oo Oddzial W Czestochowie
    Lublin, 20-081, Poland
  • Lubeskie Centrum Diagnostyczne
    Świdnik, 21-040, Poland
  • Synexus Polska Sp. Z O.O. Oddzial Warszawie
    Warsaw, 01-192, Poland
  • High-Med Przychodnia Specjalistycza
    Warsaw, 01-817, Poland
  • Dermmedica Sp. Z O.O.
    Wroclaw, 51-318, Poland
  • Ico Hospital Germans Trias I Pujol
    Badalona, 08916, Spain
  • Hospital Universitari Germans Trias i Pujol
    Barcelona, 8916, Spain
  • Dermomedic
    Madrid, 28001, Spain
  • IDEI (Instituto de Dermatología Integral).
    Madrid, 28010, Spain
  • Hospital La Paz (Hospital Universitario La Paz )
    Madrid, 28046, Spain
  • Hospital Universitario de La Paz
    Madrid, 28046, Spain
09

References and documents

Publications

  • Rosmarin D, Pandya AG, Passeron T, Forman SB, Zdybski J, Amster M, Feser C, Papp KA, Nuara A, Kornacki D, Wei S, Ren H, Harris JE, Ezzedine K. Long-Term Integrated Safety Summary of Ruxolitinib Cream in Phase 3 Clinical Trials of Patients with Vitiligo. Dermatol Ther (Heidelb). 2025 Dec;15(12):3703-3716. doi: 10.1007/s13555-025-01555-3. Epub 2025 Oct 22. PubMed 41125994 ↗
  • Seneschal J, Wolkerstorfer A, Desai SR, Grimes P, Ezzedine K, Pandya AG, Kornacki D, Wei S, Passeron T, Rosmarin D. Efficacy and Safety of Ruxolitinib Cream in Vitiligo by Patient Characteristic Subgroups: Descriptive Pooled Analysis From Two Phase 3 Studies. Dermatol Ther (Heidelb). 2025 May;15(5):1227-1238. doi: 10.1007/s13555-025-01381-7. Epub 2025 Mar 29. PubMed 40156697 ↗
  • Bibeau K, Butler K, Wang M, Skaltsa K, Hamzavi IH. Psychometric Evaluation of the Facial and Total Vitiligo Area Scoring Index Instruments in the TRuE-V Phase 3 Studies. Dermatol Ther (Heidelb). 2024 Aug;14(8):2223-2234. doi: 10.1007/s13555-024-01223-y. Epub 2024 Jul 30. PubMed 39078582 ↗
  • Rosmarin D, Passeron T, Pandya AG, Grimes P, Harris JE, Desai SR, Lebwohl M, Ruer-Mulard M, Seneschal J, Wolkerstorfer A, Kornacki D, Sun K, Butler K, Ezzedine K; TRuE-V Study Group. Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo. N Engl J Med. 2022 Oct 20;387(16):1445-1455. doi: 10.1056/NEJMoa2118828. PubMed 36260792 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2019 to primary completion in Mar 2021, 17 months.

Results were first posted in Sep 2022, 1 year 6 months after primary completion. A results delay was requested in Mar 2022.

Of 18 phase 3 interventional studies under Vitiligo, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 44. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2019
First posted
Aug 15, 2019
StartActual
Oct 3, 2019
Primary completionActual
Mar 15, 2021
CompletionActual
Oct 1, 2021
Results delay requested
Mar 8, 2022
Results first posted
Sep 21, 2022
Last update
Aug 22, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 22, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04057573
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Aug 15, 2019
Start date
Oct 3, 2019
Primary completion
Mar 15, 2021
Completion
Oct 1, 2021
Results posted
Sep 21, 2022
Last update
Aug 22, 2025

Study contacts

Kathleen Butler, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ruxolitinib

Start the discussion